Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma.

Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment.

Previous treatment with mammalian target of rapamycin (mTOR) inhibitors (sirolimus, temsirolimus, everolimus)

Intolerance or hypersensitivity to octreotide, everolimus, or other rapamycins.

Severe or uncontrolled medical conditions

Chronic treatment with corticosteroids or other immunosuppressive agent.

Other primary cancer within 3 years.

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor